Hare
HomeInsights

INDUSTRY:

Pharma

TOPIC:

Products & Services, Business & People

TITLE:

NICE: New technology appraisal on medicines used to treat recurrent ovarian cancer

BRIEF:

The National Institute for Health and Care Excellence (NICE) issued evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine.

LEGAL IMPLICATIONS:

BUSINESS IMPLICATIONS:

Special Report

In an unexpected move, just before the end of 2011, ...

Case Study

Improving expenditure efficiency has been, for a ver...

Your Portal Link to Mass Media Universe.

Valuable Quarterly Romanian Market Analysis.

Ask the analyst

Tailor-made advice for you

Feature Company